retinal vascularization
Recently Published Documents


TOTAL DOCUMENTS

50
(FIVE YEARS 16)

H-INDEX

12
(FIVE YEARS 1)

2021 ◽  
pp. 112067212110640
Author(s):  
Sadik Etka Bayramoglu ◽  
Nihat Sayin

Purpose To compare retinal vascularization progression rate, final retinal vascularization, and fluorescein angiography (FA) findings in infants who received intravitreal bevacizumab (IVB) treatment in one eye and with spontaneous regression in the other eye. Methods Thirty eyes of 15 infants who underwent IVB in one eye due to asymmetric retinopathy of prematurity, and who had pre-treatment fundus photographs and fluorescein angiography images were included in the study. Horizontal disc diameter (DD), optic disc-to-fovea distance (FD), and the length of temporal retinal vascularization (LTRV) distance were measured by evaluating pre-treatment and FA images. Results The mean ages at the time of treatment and FA were 40.38  ±  3.35 and 68.72  ±  10.52 weeks postmenstrual age, respectively. The pre-treatment LTRV/FD ratio was 3.11  ±  0.41 in the treated eyes and 3.26  ±  0.43 in the non-treated eyes (p  =  0.053). The final LTRV/FD ratio was 4.23  ±  0.38 in the treated group and 4.33  ±  0.37 in the non-treated group (p  =  0.286). Staining of the vessels, hyperfluorescent focus, and irregular branching of the vessels were similar between the groups, respectively (p  =  1.000; p  =  0.250; p  =  0.625). Conclusion The progression rate of retinal vascularization and angiographic findings were similar between the treated eyes and the non-treated eyes. Our study suggests that incomplete retinal vascularization in eyes treated with anti-vascular endothelial growth factor (VEGF) is due to the nature of the disease, and anti-VEGF treatment was not to cause cessation in vascular progression.


2021 ◽  
Author(s):  
Qionglei Zhong ◽  
Shaoli Wang ◽  
Siying Chen ◽  
Xingyue Chen ◽  
Lizhen Han ◽  
...  

Abstract Objective: To compare the recurrence rate of retinopathy of prematurity (ROP) after treatment with 0.3 mg vs. 0.25 mg ranibizumab. Subjects: All patients with ROP who underwent intravitreal injection of ranibizumab in Hainan General Hospital between January 2014 and May 2020 were included in this study. Methods: 82 cases (146 eyes) who received intravitreal injection of 0.25 mg ranibizumab were included in the conventional-dose group, and 59 cases (108 eyes) who received intravitreal injection of 0.3 mg ranibizumab were included in the high-dose group. The two groups were further divided into the 25-28-week, 29-31-week, 32-34-week, and 35-36-week GA subgroups. The differences between the conventional-dose group and the high-dose group in gestational age (GA), birth weight(BW), age at initial injection(weeks), incidence of systemic diseases, the recurrence rate of ROP, and age at retinal vascularization completed(weeks) were analyzed. Results: GA, BW, age at initial injection, and the incidence of systemic diseases were not significantly different between the conventional-dose group and the high-dose group (p>0.05). The recurrence rates of ROP were significantly lower in the 25-28-week, 29-31-week, and 32-34-week subgroups of the high-dose group than in the same subgroups of the conventional-dose group (p<0.05). Within the conventional-dose group, the recurrence rate of ROP was significantly lower in the 32-34-week and 35-36-week subgroups than in the 25-28-week and 29-31-week subgroups (p<0.05). Within the high-dose group, the recurrence rate of ROP was not significantly different between the four subgroups (p>0.05). Retinal vascularization was completed at a later age in the 32-34-week subgroup of the high-dose group than in the 32-34-week subgroup of the conventional-dose group (p<0.05) but was not significantly different between the two groups at any other GA range (p>0.05). No severe ocular or systemic complications occurred in any patient. Conclusion: Treatment with 0.3 mg ranibizumab can reduce the recurrence rate of ROP without prolonging retinal vascularization or causing serious systemic complications. Therefore, this dose may be an appropriate therapeutic dose for ROP.


2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Astrid Roeh ◽  
Julia Schoenfeld ◽  
Raffaela Raab ◽  
Viola Landes ◽  
Irina Papazova ◽  
...  

Author(s):  
Paul S. Marinec ◽  
Kyle E. Landgraf ◽  
Maruti Uppalapati ◽  
Gang Chen ◽  
Daniel Xie ◽  
...  

2021 ◽  
Vol 1 (3) ◽  
pp. 414
Author(s):  
Franco Benvenuto ◽  
LuisDiaz Gonzalez ◽  
MaríaCeleste Mansilla ◽  
Adriana Fandiño

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0243236
Author(s):  
Beatriz Cordon ◽  
Elisa Vilades ◽  
Elvira Orduna ◽  
María Satue ◽  
Javier Perez-Velilla ◽  
...  

Purpose To investigate superficial retinal microvascular plexuses detected by optical coherence tomography angiography (OCT-A) in multiple sclerosis (MS) subjects and compare them with healthy controls. Methods A total of 92 eyes from 92 patients with relapsing-remitting MS and 149 control eyes were included in this prospective observational study. OCT-A imaging was performed using Triton Swept-Source OCT (Topcon Corporation, Japan). The vessel density (VD) percentage in the superficial retinal plexus and optic disc area (6 x 6 mm grid) was measured and compared between groups. Results MS patients showed a significant decrease VD in the superior (p = 0.005), nasal (p = 0.029) and inferior (p = 0.040) parafoveal retina compared with healthy subjects. Patients with disease durations of more than 5 years presented lower VD in the superior (p = 0.002), nasal (p = 0.017) and inferior (p = 0.022) parafoveal areas compared with healthy subjects. Patients with past optic neuritis episodes did not show retinal microvasculature alterations, but patients with an EDSS score of less than 3 showed a significant decrease in nasal (p = 0.024) and superior (p = 0.006) perifoveal VD when compared with healthy subjects. Conclusions MS produces a decrease in retinal vascularization density in the superficial plexus of the parafoveal retina. Alterations in retinal vascularization observed in MS patients are independent of the presence of optic nerve inflammation. OCT-A has the ability to detect subclinical vascular changes and is a potential biomarker for diagnosing the presence and progression of MS.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Ji Hye Jang ◽  
Yu Cheol Kim

Abstract In preterm birth, the immature retina can develop a potentially blinding disorder of the eye known as retinopathy of prematurity (ROP). The vaso-proliferative phase of ROP begins at an approximate postmenstrual age (PMA) of 32 weeks. There is little or no evidence of an association between ROP development and retinal status in the early vaso-proliferative phase. We aimed to evaluate the retinal vascular findings of infants at 33–34 weeks PMA to determine their risk of ROP. We reviewed 130 serial wide-field retinal images from 65 preterm infants born before the gestational age of 31 weeks. ROP occurred more frequently in infants having a leading vascular edge within posterior Zone II. This was in contrast to normal infants, who are characterized by complete retinal vascularization up to Zone II at 34 weeks PMA. The probability of ROP development in preterm infants with retinal edge hemorrhage was 24.58 times higher than in preterm infants without retinal edge hemorrhage. Eyes with ROP that required treatment showed significantly delayed retinal vascularization accompanied by pre-plus disease. In conclusion, retinal status in the early vaso-proliferation phase might determine the risk of ROP.


Sign in / Sign up

Export Citation Format

Share Document